NCT00003816View on ClinicalTrials.gov

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

October 19, 1998

Primary Completion Date

July 12, 2019

Study Completion Date

July 12, 2019

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesNonmalignant NeoplasmUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

anti-thymocyte globulin

Given IV

DRUG

busulfan

Given IV

DRUG

carboplatin

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

DRUG

fludarabine phosphate

Given IV

DRUG

melphalan

Given IV

DRUG

thiotepa

Given IV

RADIATION

total-body irradiation

Given twice daily for 3 days

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00003816 - Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | Biotech Hunter | Biotech Hunter